Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miles

This article was originally published in The Tan Sheet

Executive Summary

Acquires 28.3% of generic drug company Schein for approximately $310 mil. Miles and Schein, which calls itself the "leading multisource pharmaceutical manufacturer" in the U.S., reported Feb. 17 that, under the strategic alliance, they will "analyze and identify potential areas of cooperation in product sourcing, production, distribution and marketing of current and future Schein and Miles products in the U.S. and abroad." Miles' agreement with Schein follows similar deals between Hoechst AG and Copley and between Marion Merrell Dow and Rugby
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082484

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel